P

Pfizer

Makes cancer drugs, vaccines and other medicines

Regulatory Affairs Manager

Full-TimeUpdated Deadline 11/30/26
No salary listed
Senior, Expert
Bachelor's, Master's, MBA
Makati, Metro Manila, Philippines
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor's degree or equivalent in Pharmacy, Life Sciences, Business, or Information Technology is required; relevant professional experience may be considered.
  • At least 5 years of experience is required for Manager and 7 years for Senior Manager.
  • Fluent English is required.
  • Demonstrated technical aptitude and ability to quickly learn and use new software, regulations, and quality standards.
  • Advanced Microsoft Office Suite skills.
  • Demonstrates deep regulatory operations knowledge and technical expertise in regulatory submissions and lifecycle management.
  • Demonstrates leadership and decision-making autonomy, guiding teams through medium-to-complex regulatory and operational challenges.
  • Quickly learns and applies regulatory processes, systems, tools, and procedures while meeting timelines and compliance requirements.
  • Builds collaborative relationships and communicates effectively across functions, teams, and stakeholders.
  • Leads project and team deliverables through collaboration, attention to detail, and effective execution.
  • Adapts to a dynamic regulatory environment and balances quality, compliance, and business priorities.
  • Maintains commitment to compliance, quality, continuous learning, and operational excellence.
  • Applies critical thinking and sound judgment to evaluate options, assess risks, and make informed decisions.
  • Demonstrates creativity, adaptability in real time, and ability to deal with ambiguity.
  • Plans, manages, and measures work to drive results.
  • For Senior Manager, demonstrates advanced regulatory operations and submission management expertise for complex activities and submissions.
  • For Senior Manager, independently identifies, analyzes, and resolves complex issues, and determines when escalation or broader stakeholder engagement is needed.
  • For Senior Manager, demonstrates proficiency in regulatory systems, workflows, and document management tools, and ability to learn new technologies, processes, and standards.
  • For Senior Manager, plans, prioritizes, and manages multiple projects and competing deadlines while maintaining quality, compliance, and customer focus.
  • For Senior Manager, communicates complex information, analyses, and difficult messages clearly to diverse audiences; influences stakeholders, translates complex concepts into actionable insights, drives alignment, and leads communications during change initiatives.
  • For Senior Manager, demonstrates urgency, decisiveness, ability to work hard, and ability to manage high work volume.
  • For Senior Manager, cultivates partnerships across global, regional, and local stakeholders to drive alignment and cross-functional priorities.
Responsibilities
  • Provides operational regulatory support for designated countries, clusters, and/or regions.
  • Supports submission logistics and technical aspects, and ensures development and delivery of cross-regional, regional, and/or national regulatory dossiers from initial application through lifecycle updates.
  • Partners with the Country Regulatory Strategist, International Labeling & Artwork, and other stakeholders to enable timely, high-quality submissions and sustained compliance.
  • Plans regulatory submission timelines and ensures regulatory systems are up to date.
  • Authors, delivers, and/or coordinates local, submission-ready Module 1 dossier components, excluding labeling and artwork.
  • Authors responses to simple local-only Health Authority queries.
  • Escalates submission plan delays and develops mitigation strategies aligned with assessed impact and associated risks.
  • Performs quality review or approval of dossier structure for applicable submissions when required.
  • Supports country Regulatory teams with tenders, out-of-stock reporting, Annual Product Quality Reviews, risk minimization plans, and regulatory input for launch planning.
  • Identifies opportunities to streamline end-to-end regulatory processes using digital tools where applicable.
  • Leads and coordinates moderately to highly complex regulatory submissions, including growth and complex lifecycle submissions, for assigned products in line with business priorities.
  • Delivers designated tasks accurately and on time in accordance with applicable policies, standard operating procedures, work instructions, guidelines, and service-level agreements.
  • Authors, reviews, and maintains local regulatory documents and Module 1 dossier components for assigned submission categories, markets, or products.
  • Manages and coordinates receipt of components, translation, dossier compilation, local ancillary legalization, and submission readiness for timely Health Authority submissions.
  • Tracks and develops action plans to maintain or improve operational performance against portfolio management, data health, key performance indicator, quality metric, and audit targets for responsible markets and clusters.
  • Monitors submissions against milestones and ensures timely, high-quality dossier components and submissions that meet business-critical timelines and regulatory requirements.
  • Manages authoring of simple Health Authority query responses and coordinates with relevant subject-matter experts and functions on more complex queries based on the Country Regulatory Strategist's response strategy.
  • Coordinates support for tenders, out-of-stock reporting, Annual Product Quality Reviews, local audit readiness, risk minimization activities, Dear Healthcare Professional Communications, medical information requests, and other regulatory operations activities.
  • Partners with cross-functional stakeholders and third-party partners to deliver regulatory priorities and operational plans.
  • Communicates and escalates issues that may affect timelines, quality, compliance, or business commitments, including Quality Events affecting responsible processes or deliverables.
  • Maintains required training curricula and continued proficiency in regulatory processes, submission requirements, tools, and systems.
  • Identifies, evaluates, and implements improvements to submission processes, regulatory operations workflows, and dossier execution efficiencies locally, regionally, and globally.
  • Leads or contributes to projects affecting people, processes, technology, and operational excellence across RIO and GRS.
  • Partners with global colleagues and key stakeholders on critical, high-priority, and accelerated submissions.
  • Leads regulatory submission project management activities, including timelines, work plans, deliverables, risk assessments, and mitigation strategies.
  • Monitors submission progress, proactively identifies and resolves issues affecting quality, compliance, resources, or timelines, and supports corrective and preventive actions for relevant Quality Events.
  • Represents regulatory operations in project meetings, advocates realistic deliverables, communicates risks, and provides submission status updates.
  • Contributes to forecasting and resource planning, supporting flexible resourcing and global workload sharing.
  • Drives adoption of standardized document authoring, publishing, management, and archival processes.
  • Applies regulatory and operational knowledge to complex projects and regulatory initiatives.
  • Supports development of digital and automation solutions that simplify regulatory processes, improve efficiency, optimize resource utilization, and support continuous improvement.
  • Leads discussions for complex regulatory projects and aligns submission strategies across global, regional, and local stakeholders.
  • Promotes continuous learning, digital fluency, innovation, collaboration, and operational excellence through digital solution adoption or leadership, problem-solving, and stakeholder engagement.
  • Leads portfolio activities, including planning and monitoring major applications and lifecycle portfolio planning under internal and external constraints.
  • Acts as a publishing expert or leader and project manager for complex or major submissions, with matrix oversight of publishing teams and vendors as applicable.
  • Leads or contributes as a workstream lead or subject-matter expert in subfunctional activities and regulatory improvement projects.
  • Provides subject-matter expertise to non-portfolio continuous-improvement and GRS transformation projects, represents RIO, and contributes to RIO and GRS improvement initiatives.
  • Serves as a regulatory operations leader and subject-matter expert, driving best practices and capability development across teams and markets.
  • Exercises independent problem-solving, navigates ambiguity, and escalates when needed.
  • Applies domain expertise to submission strategies and business outcomes.
  • Anticipates internal and external risks and partners with stakeholders to mitigate them.
Desired Qualifications
  • Multilingual skills, including Portuguese for the Latin America Execution Hub.
  • Familiarity with pharmaceutical organizational structures, systems, and culture.
  • Understanding of country and cluster regulatory requirements and trends.
  • Relevant experience in pharmaceutical regulatory, quality, and/or compliance fields.
  • Education to master's level, such as an MS or MBA in a scientific, technical, or information management discipline; relevant professional experience will also be considered.
  • Effectively uses approved artificial intelligence solutions to improve productivity, decision-making, process execution, and operational efficiency.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

-3%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 27th, 2026
AT&T, Pfizer and Zoetis offer yields up to 5.8% with shares under $100

Rising interest rates and bond yields have made dividend stocks less appealing, pushing many lower and their yields higher. Three that trade below $100 are AT&T, Pfizer, and Zoetis, according to The Motley Fool. AT&T trades around $21, down about 16% this year, with a price-to-earnings (P/E) multiple of 11 against 23 for the S&P 500. It yields 5.3% after revenue grew more than 5% in the September quarter. Pfizer trades near $30 and yields 5.8%. Its forward P/E is 10, though its shares are down more than 30% over five years. Zoetis, down 37% this year, trades below $80 with a P/E of 13 and a yield of about 2.6%. Its payout ratio is around 34% of earnings, and it has 12 potential blockbusters in its pipeline.

Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.